JP2024525145A5 - - Google Patents

Info

Publication number
JP2024525145A5
JP2024525145A5 JP2023576415A JP2023576415A JP2024525145A5 JP 2024525145 A5 JP2024525145 A5 JP 2024525145A5 JP 2023576415 A JP2023576415 A JP 2023576415A JP 2023576415 A JP2023576415 A JP 2023576415A JP 2024525145 A5 JP2024525145 A5 JP 2024525145A5
Authority
JP
Japan
Prior art keywords
leukemia
pharmaceutical composition
composition according
compound
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023576415A
Other languages
English (en)
Japanese (ja)
Other versions
JP7864745B2 (ja
JP2024525145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/099089 external-priority patent/WO2022262796A1/en
Publication of JP2024525145A publication Critical patent/JP2024525145A/ja
Publication of JP2024525145A5 publication Critical patent/JP2024525145A5/ja
Application granted granted Critical
Publication of JP7864745B2 publication Critical patent/JP7864745B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023576415A 2021-06-17 2022-06-16 がんなどの疾患の治療のための(r)-n-エチル-5-フルオロ-n-イソプロピル-2-((5-(2-(6-((2-メトキシエチル)(メチル)アミノ)-2-メチルヘキサン-3-イル)-2,6-ジアザスピロ[3.4]オクタン-6-イル)-1,2,4-トリアジン-6-イル)オキシ)ベンズアミドベシル酸塩 Active JP7864745B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021100466 2021-06-17
CNPCT/CN2021/100466 2021-06-17
CN2022091677 2022-05-09
CNPCT/CN2022/091677 2022-05-09
PCT/CN2022/099089 WO2022262796A1 (en) 2021-06-17 2022-06-16 (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer

Publications (3)

Publication Number Publication Date
JP2024525145A JP2024525145A (ja) 2024-07-10
JP2024525145A5 true JP2024525145A5 (cg-RX-API-DMAC7.html) 2025-06-03
JP7864745B2 JP7864745B2 (ja) 2026-05-25

Family

ID=82196389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576415A Active JP7864745B2 (ja) 2021-06-17 2022-06-16 がんなどの疾患の治療のための(r)-n-エチル-5-フルオロ-n-イソプロピル-2-((5-(2-(6-((2-メトキシエチル)(メチル)アミノ)-2-メチルヘキサン-3-イル)-2,6-ジアザスピロ[3.4]オクタン-6-イル)-1,2,4-トリアジン-6-イル)オキシ)ベンズアミドベシル酸塩

Country Status (16)

Country Link
US (1) US20260125387A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355747A1 (cg-RX-API-DMAC7.html)
JP (1) JP7864745B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240021808A (cg-RX-API-DMAC7.html)
CN (2) CN117597348A (cg-RX-API-DMAC7.html)
AU (1) AU2022292697A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220099A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003731A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023018577A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000260A (cg-RX-API-DMAC7.html)
IL (1) IL309359A (cg-RX-API-DMAC7.html)
MX (1) MX2023014890A (cg-RX-API-DMAC7.html)
PE (1) PE20240923A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023553300A1 (cg-RX-API-DMAC7.html)
UY (1) UY39823A (cg-RX-API-DMAC7.html)
WO (1) WO2022262796A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
KR20250170131A (ko) 2023-04-17 2025-12-04 얀센 파마슈티카 엔브이 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물
KR20260099138A (ko) 2023-10-20 2026-06-26 얀센 파마슈티카 엔브이 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법
KR20260115654A (ko) 2023-12-04 2026-07-24 쇼우야오 홀딩스 (베이징) 코., 엘티디. 치환된 다환 화합물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
AU2017212572A1 (en) 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
TWI753016B (zh) 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー,インク. メニン阻害剤を用いた血液悪性腫瘍の処置
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal

Similar Documents

Publication Publication Date Title
RU2606497C2 (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2485122C2 (ru) Соединения и композиции, ингибирующие parp, и способы их применения
JP2015512942A5 (cg-RX-API-DMAC7.html)
CA2850564A1 (en) Compounds useful as inhibitors of atr kinase
EP2868660B1 (en) Antitumor effect potentiator comprising an imidazooxazine compound
US20090093495A1 (en) Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases
CN105592850B (zh) Ack1/tnk2酪氨酸激酶的抑制剂
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
WO2017049462A1 (zh) 一类新型的flt3激酶抑制剂及其用途
TWI453201B (zh) 可作為Hsp90之抑制劑之異吲哚衍生物
JP2022523368A5 (cg-RX-API-DMAC7.html)
CN112236426A (zh) 制备2,4,5-三取代的1,2,4-三唑酮的方法
JP2025131661A (ja) 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態
CA2671336A1 (en) Epothilone analogues modified at positions c12-c13 as anticancer drugs
JP2012255038A (ja) 異常な細胞増殖の治療用のピリミジン誘導体
CA3195465A1 (en) Succinate and crystal form thereof as therapeutics
TW202245746A (zh) N-((r)-2,3-二羥基丙氧基)—3,4—二氟—2—(2—氟—4—碘—苯基胺基)—苯甲醯胺之基本上純的形式iv之組合物及其用途
CN113382997A (zh) 盐酸罗加替尼的一水合物及其固体状态
EP4663628A1 (en) New compound and pharmaceutical composition comprising same
CN112442105B (zh) 作为蛋白激酶抑制剂的嘧啶并[4,5-d]嘧啶-2-酮衍生物
WO2022083679A1 (en) Prodrugs for sustained releasing therapeutic agents and uses thereof
KR102759785B1 (ko) CCL2 발현을 억제하는 1-aryloxymethyl-2,4,5-trifluorobenzene 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
EP2924045A1 (en) New agents for the treatment of cancer
WO2016197981A1 (zh) 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
HK40065028A (en) The monohydrate of rogaratinib hydrochloride and solid states thereof